These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30621280)

  • 1.
    Leshem Y; Pastan I
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30621280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of anti DLL4 Nanobody fused to truncated form of Pseudomonas exotoxin: As a novel immunotoxin to inhibit of cell proliferation and neovascularization.
    Mohammadlou M; Salehi S; Baharlou R
    Anal Biochem; 2022 Sep; 653():114776. PubMed ID: 35679954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials with Pseudomonas exotoxin immunotoxins.
    Pai LH; Pastan I
    Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
    Wu T; Zhu J
    Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
    Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
    Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
    Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights on
    Morgan RN; Saleh SE; Farrag HA; Aboshanab KM
    Ther Deliv; 2023 Jan; 14(1):31-60. PubMed ID: 36950853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin.
    Pai LH; Wittes R; Setser A; Willingham MC; Pastan I
    Nat Med; 1996 Mar; 2(3):350-3. PubMed ID: 8612238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
    Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
    Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
    Leshem Y; King EM; Mazor R; Reiter Y; Pastan I
    Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30441807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain II of
    Müller F; Cunningham T; Beers R; Bera TK; Wayne AS; Pastan I
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29883379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: BL22, NCI.
    Barth S
    Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL13 Fused
    Uludağ D; Karakaş N
    Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
    Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
    Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
    Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
    Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis.
    Brenner T; Steinberger I; Soffer D; Beraud E; Ben-Nun A; Lorberboum-Galski H
    Immunol Lett; 1999 Jun; 68(2-3):403-10. PubMed ID: 10424450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.